{"name":"Hangzhou Yirui Pharmaceutical Technology Co., Ltd","slug":"hangzhou-yirui-pharmaceutical-technology-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"YR001 Dose A on low body surface area","genericName":"YR001 Dose A on low body surface area","slug":"yr001-dose-a-on-low-body-surface-area","indication":"Other","status":"phase_1"},{"name":"YR001 Dose B on middle body surface area","genericName":"YR001 Dose B on middle body surface area","slug":"yr001-dose-b-on-middle-body-surface-area","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"YR001 Dose A on low body surface area","genericName":"YR001 Dose A on low body surface area","slug":"yr001-dose-a-on-low-body-surface-area","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"YR001 Dose B on middle body surface area","genericName":"YR001 Dose B on middle body surface area","slug":"yr001-dose-b-on-middle-body-surface-area","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMingJBVV95cUxQdEFnQktFM210eXdiZmRhVlE4Y3FUTndfak5Cell5OFgyR1Z1QWxsaks4TzU0NTBvZlJIc0o3enpwWTlTYXBFR3o4eFZNZUg2QUpEZGN5Z3ZsTFRqTmZOMVBSZVpoa1YxT3ZHbFlaVVJOZHBWZjFkSE1jSFpXSVVpYVl2U1VhSHRJS1daVHZkSHAtLW5nbW1aeWZIZk9CQUxLNnVlYVF6VVZNRVdtT3ZpVzhMVkI1ODFPLUpqLWpBU3dEVnpWSldBX1JaTmZaX1VTUFJEc0hubWtXZGVwWmw4UmlyLUpTbk5MYVhCRENwaVByRVhzZXhobF9wUGJNYzUtMGNzWEFqbkN3enFKdFplVjJnYzVPQVduMDAzZ1Jn?oc=5","date":"2025-12-08","type":"regulatory","source":"GlobeNewswire","summary":"Eczema Clinical Trial Pipeline Accelerates as 100+ Pharma - GlobeNewswire","headline":"Eczema Clinical Trial Pipeline Accelerates as 100+ Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgJBVV95cUxNbURGeFBVM19lWjJINGlwR01HamQ5X2traTA5bllxU0gyWkd6M21MeElyZXhHTzR2LUhvZ0tsbmNzZXVoVFp0bTc0a1pNZmxDaDFNTkxXT2RWNVpYZG5CZWpBYWNGNTVPVUVGQzJwYUY2YWpTb2hWMGJDSU5tUE9OMmlHOHNScHZDM3ZZRE5YXzFRTXZzT1BkYVFKWUlNN2g1YTh1aHJKN1h3eTJ2cTFFdzdVbnVHV05EWDQ0SVB6VEZDOFdkQzU2QUhyQXRXT3BmbDY0eDllY0R6LUhNaHo0dkU0dWtNUjJ5OGFteEdSUzM4SWlZVVRnX2ZDUWFMZmRKVmZXRllhZDNHN3QzLVRabWZERlhTV0JCTWdaQ1JUdmpqbkY5OHpNb053SUdRUQ?oc=5","date":"2025-10-23","type":"trial","source":"GlobeNewswire","summary":"Hidradenitis Suppurativa Clinical Trial Analysis: Key - GlobeNewswire","headline":"Hidradenitis Suppurativa Clinical Trial Analysis: Key","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxOSkFOUFNlZC1BR0tYYkdSdGdWREZHMGZPR1d3U2J5czVzMFZhX0N4SFhkcWw5V3pfS3BvSzNsZGdFRElyUGkxd1RyREd1SkJ0X2FVSy1tZW94OHdWclVBTlNkMy1TSWlQNE9IUGRSQnJaazZ6U1FrYUQ1bFYzNUFLdkZ5djdFXzZyd0RlQldLWlIxc3daNXAtMjNzbG5xWklRd1hUMkM5S29VZUxrSkRCUlY3eHN2SzB5YndTRG1aQ05CMVZ6Wlg2Z2oweE9uVWlkNVk1Q01Dd0pRcXhrb2p3ZXJ1cFJqRFJsbWllWU1rbURVOWFYU0R6bm0yVXg?oc=5","date":"2025-05-12","type":"trial","source":"PR Newswire","summary":"Chronic Pruritus Market is Anticipated to Expand at a CAGR of 8.6% During the Study Period (2020-2034) | DelveInsight - PR Newswire","headline":"Chronic Pruritus Market is Anticipated to Expand at a CAGR of 8.6% During the Study Period (2020-2034) | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxNMEM0S2RNSkg5N2h3NExOWWF0ZFRkTlBFXzFiN2tfWGIyNUJaWkluQ3NsN3BrVE5xbEdaeHZNMFJkRjgtZVU4RU90eENnbmxSaFIyWjlkM0RGSTYwc1NRQUY3cHZxSGdnekNWR3BKWmZmWXphMHh1NlJlc0poSHBYOGxmdnU0YW9VeS05RDZvMDBkd2pHTVZDc2dwQ2IwdUQ3d1lfTkFENHd2N2ZuazVUQTJ0RUFGQjNXamRkM3JnZnRjVlJEYkJxcjRadVVNTTFWcFNPT2NCOFN4Rjh5ZGRJOVVpSW5TMkNjQ2Q0?oc=5","date":"2025-01-13","type":"trial","source":"PR Newswire","summary":"Exosome Therapies Market Poised for Explosive Growth During the Study Period (2025-2034) | DelveInsight - PR Newswire","headline":"Exosome Therapies Market Poised for Explosive Growth During the Study Period (2025-2034) | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggJBVV95cUxQdW1sdGRET3RScEdZbzNjWVhfTTBLRTR2a0Z3T19fZktmaVF2Y1FTdFRFbkdKcEs2aEZnR1ZRU3VKUmNVWjFiQmR4b3RTWWdFZFZyMUNXUW9ZNEstV3Azdnc2V0VIWlVkNG1qQ09fVVBkNU14d1E3ZFVTcjExOU1Vdmdva09OZWpicEc1eVJXWWc1RE9JcE1xU24wNWtpS2FaNXZ6MXhRM0RYeVNYMkVwMjYxVzZzQm8zN0FDRlB2X3cwNlVhLUtVQ0NIek43M0d4OE52R0Y3VkVZUnpTTXFNUTBZbnpHRzljNDFkVk1PNE5NVFJGZHhDbG9lMUdNLVRuS2c?oc=5","date":"2024-11-20","type":"regulatory","source":"GlobeNewswire","summary":"Hidradenitis Suppurativa Market to Showcase Remarkable Growth at a CAGR of 12.4% by 2034 | DelveInsight - GlobeNewswire","headline":"Hidradenitis Suppurativa Market to Showcase Remarkable Growth at a CAGR of 12.4% by 2034 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxPSS0yM0NPRGx0dnBxdjFLbXJ0NEpZVDR3Zzd3VnZSVWY5NE5VODJHVzRUaU5USVhVS2MzaG5EMHNCTzRlVmR4b2w1NFJtenJTVnhLbFVYekR6VXJKVkZnY3FUSkxPa3ZZTVhGMlBwT09nYmpxLW8tYVpFZ0UzQmI4UXJUenlkd050cDJweXRSM3ZhTDAyYTI4WE5iZ2RodFdiUmdDRWE5aW5PRmVZdXVfSy10SUlNSTU4SVFvcnpLOXRPQ242eXRxcDlxOWt0eUlXRVE?oc=5","date":"2024-11-13","type":"pipeline","source":"PR Newswire","summary":"Global Dermatological Drugs Market to Cross USD 31 Billion by 2030 | DelveInsight - PR Newswire","headline":"Global Dermatological Drugs Market to Cross USD 31 Billion by 2030 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxPeThLUHJyLVFiTEZNQV96VlJnRzhXSTh5M1lEanJ6WnE3Sy05RXcyLXRYZGJRbExnSk5BdTdudjhKd1FCMUZjejduNUt0Uy1NTVZ4UEhONjZ0WVNwMmxRNEh6RnNmNm9yZ2NqM2xTZTFJVzQ1RzBaR1RLdFdCRG5FNnZRcldIdU5ic0NvZy11UEk0THR5Vmo2ZDI2VGVyaWhic3Y1Zm1ka2s5ZE1xcDhPd2NVWkUxUGVzc0JIVlFiOVZHejZudmpfRWZVUGlFM2tfcVlnMC1aczV6YjhoUk13NDRVbURFbXVLM1E?oc=5","date":"2024-11-04","type":"pipeline","source":"PR Newswire","summary":"Exosome Therapies on the Rise as 70+ Major Companies Driving Development in the Field | DelveInsight - PR Newswire","headline":"Exosome Therapies on the Rise as 70+ Major Companies Driving Development in the Field | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxPd3duWlFZcnJ5VUpJTmRLbVRGTkl2aEVHVk9JZ2lMa2h6YXNCVnQ3a0ZQZnYzVnlFQlhHdmItNGI1NUJQSTdUa0EyZFZRSWJqRTQ0dnZsZTdnZFFhNXZDdVEtNFdWclZfNmZzcE5MYXBlT2JnMmV3NVR4QWhyRlNraWZoSllBYnIxbkkwc0puUE9KWnIxcnc0QmFpeHJUN2dOeWpmTFp2TnNKU1ExZTZBdG1iN1BxWkVsM053OVppNHFkdF84V2dnUkVqQmxpeGR1S2MxZEI2MWhfczZmSnh4XzhyclQ?oc=5","date":"2024-10-29","type":"pipeline","source":"GlobeNewswire","summary":"Global Exosome Market to Surge at a Tremendous CAGR of ~20% by 2030 | DelveInsight - GlobeNewswire","headline":"Global Exosome Market to Surge at a Tremendous CAGR of ~20% by 2030 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAJBVV95cUxOZjYwbklrS0dFNERFOXV2eW1rRXlZWkRkU1hRREZLZDUzeUZORExqTnpaRmJXYi1aclE2OVFLRVZRSVQ1SVRlX2hWaVZQUlhRcEsySFdVV0J0akFpQXJFQXY4ZExWaDNhbmI0b0FLUEExSGZEcXpmaE9ZUFhnd3p6QWRhcGNpVHhmZ0U3aGVWcDN2V0tia09jNVdQX3VQUDJncWpEd0NBcnRoVWxmWldFcUdyVG9jMW9lMXdHVXMyQ1laUzVKN0RncDlMUlhRSFJqOC0xYlpDM3k0YWNNQTdzTjl1SldDQ1V3ZGtrQlY5b1k5Ym9icWprbDdaYkkxU1BHUzR0V1g4VTNzRW05REdWamJsVnowMmJzaU9nMkMwU2pjSVNP?oc=5","date":"2024-07-11","type":"trial","source":"PR Newswire","summary":"Molecular Glues Clinical Trial Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - PR Newswire","headline":"Molecular Glues Clinical Trial Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Therapeutic","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_1":2},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}